By Takoda Roland, Clinical Research Consultant
I have long been a proponent of the potential of eSource and its advantages in clinical trials. From my experience as a CRA (Clinical Research Associate) I first wrote about eSource in November 2018, SOCRA and January 2019, ACRP, which enabled me to see that clinical research was only just scratching the surface on leveraging eSource to fundamentally change the way we monitoring clinical trials. At the time, I did not expect to find myself in a position to make a meaningful shift towards remote monitoring. Several years later, while working as a CTM (Clinical Team Manager) on Phase III Global Pivotal IND NASH (Non-alcoholic steatohepatitis) study, COVID forced CROs (Contract Research Organizations) to rethink their monitoring paradigm. Drawing from both my own and my team’s experience with Clinical Research IO (CRIO), our study was able to successfully implement a remote monitoring process to mitigate the issues of running a clinical trial during a pandemic. CRIO is the leader in eSource with over 1,000 sites globally using their technology, and it was already being used at several of our sites. Even as someone who had long advocated for remote monitoring using eSource, I found myself astounded at the success our team achieved.